Adagene Announces Pricing of US$70.0 Million Public Offering of ADSs
Adagene Inc., a clinical-stage biotech company specializing in novel antibody-based cancer immunotherapies, announced the pricing of an underwritten public offering of 18.67 million ADSs at $3.75 each, raising gross proceeds of approximately $70 million. The offering attracted participation from both new and existing institutional investors and is …